First Examples of Reactions of Azole N-Oxides with Thioketones: A Novel Type of Sulfur-Transfer Reaction

by Grzegorz Mlostoń* and Tomasz Gendek¹)

Department of Organic and Applied Chemistry, University of Łódź, Narutowicza 68, PL-90-136 Łódź

and Heinz Heimgartner*

Organisch-chemisches Institut der Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich

Dedicated to Professor George A. Olah on the occasion of his 70th birthday

The reactions of 1,4,5-trisubstituted imidazole 3-oxides 1a-k with cyclobutanethiones 5a,b in CHCl₃ at room temperature give imidazole-2(3*H*)-thiones 9a-k in high yield. The second product formed in this reaction is 2,2,4,4-tetramethylcyclobutane-1,3-dione (6a; *Scheme 2*). Similar reactions occur with 1 and adamantanethione (5c) as thiocarbonyl compound, as well as with 1,2,4-triazole-4-oxide derivative 10 and 5a (*Scheme 3*). A reaction mechanism by a two-step formation of the formal cycloadduct of type 7 *via* zwitterion 16 is proposed in *Scheme 5*. Spontaneous decomposition of 7 yields the products of this novel sulfur-transfer reaction. The starting imidazole 3-oxides are conveniently prepared by heating a mixture of 1,3,5-triszubstituted hexahydro 1,3,5-triazines 3 and a-(hydroxyimino) ketones 2 in EtOH (*cf. Scheme 1*). As demonstrated in the case of 9d, a 'one-pot' procedure allows the preparation of 9 without isolation of the imidazole 3-oxides 1. The reaction of 1 c with thioketene 12 leads to a mixture of four products (*Scheme 4*). The minor products, 9c and the ketene 15, result from an analogous sulfur-transfer reaction (*Path a* in *Scheme 5*), whereas the parent imidazole 14 and thiiranone 13 are the products of an oxygen-transfer reaction (*Path b* in *Scheme 5*).

Introduction. – Due to our current interest in cycloaddition chemistry involving thiocarbonyl compounds, we decided to examine whether imidazole 3-oxides of type **1** undergo reactions with thioketones which were recognized as excellent dipolarophiles²). To the best of our knowledge, no reaction of an aza-aromatic *N*-oxide and a thioketone has been reported so far.

Studies on syntheses and chemical behavior of aromatic *N*-oxides are of considerable interest [4]. Several thermal and photochemical transformations gave rise to unexpected products *via* unusual mechanistic pathways [5-7]. Among intermolecular transformations with *N*-oxides, one of the most significant type involves reactions with dipolarophiles. In analogy to nitrones, aromatic *N*-oxides behave as 1,3-dipoles, and several examples of reactions with electron-deficient olefins and acetylenes as well as with isocyanates have been reported [4-8]. Imidazole *N*-oxides are well-known representatives of azole *N*-oxides, and reports on their synthesis go back to the beginning of this century (*cf.* [9]). However, 2-unsubstituted imidazole *N*-oxides **1**, being convenient starting materials for syntheses of imidazole derivatives, were reported only in the seventies by an English and a Polish group [10] [11]. Until now, there is only a very limited use of these compounds with respect to syntheses of imidazole derivatives functionalized at C(2). Described reactions of some representatives of **1** concern substitution of the H-atom at C(2) by Cl, deoxygenation, the photochemical rearrangement to the

¹⁾ Part of the projected Ph.D. thesis of T.G., University of Łódź

²) Thioketones have been shown to be the most reactive dipolarophiles towards thiocarbonyl ylides [1], Ph₂CN₂ [2], and nitrones [3].

corresponding imidazol-2-ones, as well as 1,3-dipolar cycloadditions with phenyl isocyanate and dimethyl acetylenedicarboxylate [10-12]. Recently, a smooth introduction of a CN group using Me₃SiCN has also been elaborated [12b].

The only related reactions with S-containing dipolarophiles were described by *Takahashi* and *Kano* [13]: 1-methylbenzimidazole 3-oxide and CS_2 react to give 1-methylbenzimidazole, and with phenyl isothiocyanate a similar reaction results in the formation of 1-methyl-2-(phenylamino)benzimidazole. One of the postulated mechanisms of these reactions involve a 1,3-dipolar cycloaddition with subsequent elimination of COS^3).

Results and Discussion. – To prepare imidazole 3-oxides 1, α -(hydroxyimino) ketones 2 and 1,3,5-trisubstituted hexahydro-1,3,5-triazines 3 were heated in EtOH (*cf.* [11], *Scheme 1*). The crystalline products were obtained in high yields (*Table 1*).



Table 1. Prepared 1,4,5-Trisubstituted Imidazole 3-Oxides 1

1	2	3/4	\mathbb{R}^1	\mathbb{R}^2	R ³	Yield of 1 [%]	M.p. [°]
a	a	a	Me	Me	Me	77	164-166
b	a	b	Et	Me	Me	54	61-63
с	a	с	PhCH ₂	Me	Me	95	199 - 201
d	a	d	Cyclohexyl	Me	Me	58	198 - 200
e	b	а	Me	Ph	Ph	61	255 - 257
f	b	b	Et	Ph	Ph	75	182 - 184
g	b	с	PhCH ₂	Ph	Ph	92	174-176
ĥ	b	d	Cyclohexyl	Ph	Ph	74	179 - 180
i	b	е	PhCH ₂ CH ₂	Ph	Ph	88	185-187
j	с	a	Me	Ph	Me	89	201-203
k	с	f	Bu	Ph	Me	80	155–157

Solutions of *N*-oxides **1** in CHCl₃ were treated with a slight excess of 2,2,4,4-tetramethyl-3-thioxocyclobutanone (**5a**) at room temperature. Immediately, an exothermic reaction started, and, within a few minutes, the characteristic red color of **5a** disappeared, and a colorless product precipitated. After removing the solvent, the crude mixture was analyzed by means of ¹H-NMR spectroscopy. In all cases, the characteristic Me absorption at 1.2 ppm of 2,2,4,4-tetramethylcyclobutane-1,3-dione (**6a**) appeared. Furthermore, the signal of H–C(2) of **1** at 8–8.5 ppm was no longer present. The colorless solids were washed with EtOH and recrystallized to give

³) For another proposal, see [14].

imidazole-2(3*H*)-thiones **9** in high yields (*cf. Scheme 2* and *Table 2*). Some of the products have previously been described and were identified by the comparison of their melting points and spectral data. Typically, a medium intensive C=S absorption in the IR spectrum (KBr) was registered at $1220-1150 \text{ cm}^{-1}$, and, in the ¹³C-NMR spectrum, the C(2) signal appeared at 150-160 ppm.

An identical course of reaction was observed using dithione **5b** instead of **5a**. In this case, only 0.5 equiv. of **5b** was required for a complete conversion of **1** into **9**, *i.e.*, both C=S groups of **5b** were involved in the reaction, and again **6a** was formed.



Table 2. Prepared Imidazole-2(3H)-thiones 9 from 1 and 5a

5c

6a X = O

9	\mathbb{R}^1	\mathbb{R}^2	R ³	Yield [%]	M.p. [°]
a	Me	Me	Me	83	212-214
b	Et	Me	Me	83	183-184
с	PhCH ₂	Me	Me	92	227-228
d	Cyclohexyl	Me	Me	95	221-223
e	Me	Ph	Ph	79	279-281
f	Et	Ph	Ph	96	292-294
g	PhCH ₂	Ph	Ph	95	268-270
ĥ	Cyclohexyl	Ph	Ph	95	295-297
i	PhCH ₂ CH ₂	Ph	Ph	88	261-263
j	Me	Ph	Me	94	254-256
k	Bu	Ph	Me	65	285-287

Adamantanethione $(5c)^4$) and 1 reacted as well in a very similar way, and, after a short reaction time, imidazole-2(3*H*)-thiones 9 were isolated in similar yields as from the reactions with 5a (*Table 2*). To our surprise, the reaction of 1g with thiobenzophenone was much more sluggish and was terminated only after *ca*. 30 h at room temperature. All attempted reactions with 9*H*-xanthene-9-thione or 9*H*-fluorene-9-thione failed completely. The influence of the steric hindrance of the substituent R¹ was examined in a competitive experiment in which a mixture of equal amounts of imidazole 3-oxides 1a and 1d was reacted with 0.5 equiv. of dithione 5b. Product 9a was found to be the major component in the crude mixture (¹H-NMR; 9a/9d 95:5). In a similar test with 1a and 1c, 9a and 9c were formed in almost equal amounts (ratio 45:55; ¹H-NMR). These results indicate that R¹ considerably influences the rate of the S transfer, probably at the ring-closure step of the zwitterionic intermediate 16 to give 7.

The simple procedure of the reaction of 1 and 5 together with the high yields of synthetically useful imidazole-2(3H)-thiones 9^5) prompted us to investigate whether similar conversions could be performed using other heterocyclic *N*-oxides. As an example, we tested the reaction of triazole derivative 10 with 5a (*Scheme 3*). After a fast reaction, triazole-5(4H)-thione 11 was obtained in 84% yield.



Unlike azole *N*-oxides, six-membered aromatic *N*-oxides did not undergo reactions neither with **5a** nor with **5c**. For example, solutions of substituted pyridine *N*-oxides and **5a** in CHCl₃ change the red color neither after 3 days at room temperature nor after refluxing for several hours. ¹H-NMR Analysis of the same reaction in CDCl₃ showed no change of starting materials. Several other experiments with pyrimidine-*N*-oxide derivatives⁶) were also unsuccessful. Based on these results, we conclude that the 'S-transfer reaction' resulting in the formation of heterocyclic thiones can be efficiently used in the series of azole *N*-oxides only.

Several years ago, *Schaumann* and *Behrens* reported on the reaction of thioketenes of type **12** with 1-pyrroline *N*-oxide, a cyclic nitrone, which unexpectedly led to thiiranone derivatives of type **13** and 2,3-dihydropyrrole [17]. Thus, no S but only O transfer occurred converting **12** into **13**. With respect to these results, we performed the reaction of **1c** with thioketene **12**⁷) in CDCl₃ at room temperature. After 2 h, deoxygenated imidazole **14** as well as imidazole-2(3*H*)-thione **9c** were formed in 84 and

⁴⁾ For convenience, the name adamantanethione is used for tricyclo[3.3.1.1^{3,7}]decane-2-thione.

⁵⁾ For the useability of imidazole-2(3H)-thiones, see [15][16] and refs. cit. therein.

⁶⁾ We thank Dr. S. Ostrowski, Institute of Organic Chemistry, Polish Academy of Sciences, Warsaw, for his generous gift of pyrimidine N-oxides.

⁷⁾ We thank Prof. Dr. E. Schaumann, Technical University of Clausthal, for providing us with the ketene.

15% yield⁸), respectively (*Scheme 4*). Furthermore, **12** has been transformed into thiiranone **13** in *ca*. 70% yield, and the corresponding ketene **15** was found as a minor product in *ca*. 14% yield.



When thioketene **12** was treated with pyrimidine *N*-oxide under analogous conditions, the violet color of the solution disappeared after 7 days. ¹H-NMR Analysis of the mixture showed the presence of pyrimidine and thiiranone **13**, formed in quantitative yields. The latter was isolated after chromatographic workup and characterized by the comparison of the spectral data with those reported [17].

Our results, supported by some observations described earlier, enable us to formulate a mechanistically convincing pathway for the reactions of *N*-oxides with thiocarbonyl compounds. The first step of the reaction of azole *N*-oxides with thioketones is a nucleophilic attack of the O-atom of the *N*-oxide onto the C=S group to give the dipolar intermediate **16** (*Scheme 5*). Ring closure between the S-atom and C(2) of the imidazolium ion leads to the formal [2 + 3] cycloadduct **7**. This intermediate has never been observed in our NMR experiments but decomposed, probably *via* O,S-hemiacetal **8** (*Scheme 2*), in a fast and irreversible reaction to yield the final products **8** and **6a**.

Stable 1,4,2-oxathiazolidines of type 7 have been described by *Black* and *Watson* who carried out reactions of $5\mathbf{a} - \mathbf{c}$ with both acyclic and cyclic nitrones (*e.g.*, pyrroline *N*-oxides) [18]. Some of these oxathiazolidines, upon irradiation with UV light, dissociated to give pyrrolidine-2-thiones and the ketone corresponding to 5. For this process, a thiaziridine was postulated as an intermediate. Formation of the stable oxathiazolidines was explained as the result of a 1,3-dipolar cycloaddition. In contrast to this proposal, it is likely that the reaction between 1 and $5\mathbf{a} - \mathbf{c}$ to 7 occurs stepwise *via* the initial formation of 16. An additional result supporting this mechanism is the much slower reaction of 1 with thiobenzophenone, which has been shown in several experiments to be a more reactive dipolarophile than $5\mathbf{a} - \mathbf{c}$ [1][2]⁹). Furthermore, the

⁸) Determined in the reaction mixture by means of ¹H-NMR spectroscopy.

⁹⁾ The reaction of thiobenzophenone methanide with thiobenzophenone was *ca*. 10^3 times faster than with **5a** [2a]. Reaction rates with Ph₂CN₂ showed a similar difference [2b].



17 $R^1 = PhCH_2$, $R^2 = R^3 = Me$

'superdipolarophile' thiofluorenone resisted to react with 1, and this observation is rationalized in terms of an ionic process. The polarization of the C=S bond in thiofluorenone is considerably increased in comparison with other aromatic thioketones, as the negative charge is partially delocalized within the aromatic skeleton. Therefore, the electrophilicity of the C=S C-atom is reduced, and the nucleophilic attack of the O-atom to give **16**, initiating the formation of **7**, does not occur.

The low stability of the 'cycloadduct' **7** in comparison with 1,4,2-oxathiazolidines described by *Black* and *Watson* can be understood by the fact that the dissociation of **7** into **9** and **6a** occurs by re-aromatization of the azole ring¹⁰).

The stepwise mechanism may also explain the lack of reaction of pyridine and pyrimidine *N*-oxides with thioketones. The key step of the conversion $1 + 5a \rightarrow 9 + 6a$ is the formation of zwitterion 16 which, in the case of six-membered aromatic *N*-oxides, is much less favored due to the lack of stabilization of the positive charge by the lone pair of the second N-atom.

A further evidence of the stepwise mechanism of the reaction of azole *N*-oxides with thioketones is provided by the reaction of **1c** with thioketene **12** (*Scheme 4*). In analogy to **16**, zwitterion **17** is proposed as the key intermediate (*Scheme 5*). Cyclization *via Path a* initiate a cascade of reactions which result in formation of imidazole-2(3H)-thione **9c** and the corresponding ketene **15**. However, the main product is formed *via Path b* involving formation of a thiirane ring and simultaneous cleavage of the N–O bond, yielding thiiranone **13** and deoxygenated imidazole **14**. In the slow reaction of pyrimidine *N*-oxide and **12**, apparently *Path b* is followed exclusively leading to the parent heterocycle and **13**.

In conclusion, the reaction of azole *N*-oxides with easily available cycloalkanethiones offers a simple and efficient route to azole-thiones. Taking into account that a

¹⁰) Imidazole-2(3H)-thiones like other azole-thiones are in a tautomeric equilibrium with the corresponding azole-thiole structures (cf. [15][19]).

series of differently substituted imidazole 3-oxides are easily prepared, the described reaction sequence constitutes a very useful synthesis of imidazole-2(3H)-thiones. It is especially worth mentioning that a 'one-pot' reaction has been elaborated which allows to prepare imidazole-2(3H)-thiones **9** from perhydro-1,3,5-triazines **3**, α -(hydroxy-imino) ketones **2**, and cyclobutane-1,3-dithione **5b** without isolation of the intermediate imidazole 3-oxide **1**.

We thank the analytical sections of our institutes for spectra and analyses and the *Polish National Committee for Scientific Research (KBN)*, the *Swiss National Science Foundation*, and *F. Hoffmann-La Roche AG*, Basel, for financial support. *G.M.* thanks Mrs. *M. Celeda* for technical assistance in the preparation of imidazole 3-oxides.

Experimental Part

1. General. See [20]. M.p.: in capillary, *Melt-Temp. II* (*Aldrich*) apparatus; uncorrected. IR Spectra: *Specord-71* IR spectrometer; in KBr. ¹H- and ¹³C-NMR-Spectra: *Varian-Gemini-BB* spectrometer (200 MHz (¹H) and 50.4 MHz (¹³C)); CDCl₃ soln.; TMS as an internal standard (δ (TMS) = 0). EI-MS: *Variant-MAT-112S* spectrometer; at 70 eV; CI-MS with NH₃. Elemental analyses were performed in the microanalytical laboratories of the Polish Academy of Sciences in Łódź and the Institute of Organic Chemistry of the University of Zürich.

2. Starting Materials. The perhydro-1,3,5-triazines 3a - f were prepared from the corresponding primary amines and HCHO according to known protocols: 1,3,5-trimethylperhydro-1,3,5-triazine (3a), 1,3,5-triehylperhydro-1,3,5-triazine (3b), and 1,3,5-tributylperhydro-1,3,5-triazine (3f) [21], 1,3,5-tribenzylperhydro-1,3,5triazine (3c) [22], 1,3,5-tris(2-phenylethyl)perhydro-1,3,5-triazine (3e) [23], and 1,3,5-tri(cyclohexyl)perhydro-1,3,5-triazine (3d) [24]. For preparation of diketone monoximes 2, described methods have been applied to: 3-(hydroxyimino)butan-2-one (2a) by nitrosation of butan-2-one using amyl nitrite [25], 2-(hydroxyimino)-1,2diphenylethanone (benzil monoxime; 2b) from benzil and NH₂OH-HCl hydrochloride [26], and 3-(hydroxyimino)-3-phenylpropan-2-one (2c) by nitrosation of 1-phenylpropan-2-one [27]. The 2,2,4,4-tetramethyl-3-thioxocyclobutanone (5a) and 2,2,4,4-tetramethylcyclobutane-1,3-diithone (5b) were prepared by thionation of 2,2,4,4-tetramethylcyclobutane-1,3-dione using P₄S₁₀ [28], adamantanethione (5c) was synthesized analogously from commercially available adamantanone according to [29], and (tert-butyl)(isopropyl)thioketene (11) was provided by Prof. Dr. E. Schaumann, Technical University of Clausthal, Germany. Pyridine and pyrimidine N-oxides were obtained from pyridine and pyrimidine, respectively, using H₂O₂ as oxidizing agent according to [30]. 3-(Ethoxycarbonyl)-1-phenyl-1,2,4(1H)-triazole 4-oxide (10) was obtained following the procedure described in [31].

Some imidazole 3-oxides **1** have not been described in the literature so far. Typically, they were prepared by heating 1.7 mmol of the corresponding perhydro-1,3,5-triazine **3** with 5 mmol of the corresponding diketone monoxime in boiling EtOH for 1 - 10 h; required reaction times are given. Generally, compounds **1** tend to form hydrates with variable amount of H₂O which could not be removed by boiling with benzene using a *Dean-Stark* column.

1,4,5-Trimethylimidazole 3-Oxide (**1a**): 3 h; yield 486 mg (77%). Colorless crystals. M.p. $164-166^{\circ}$ (CH₂Cl₂/Et₂O). IR: 1660*m*, 1630*s*, 1450*s*, 1400*s*, 1350*s*, 1170*m*, 1080*m*. ¹H-NMR: 8.10 (*s*, H–C(2)); 3.60 (*s*, MeN); 2.18, 2.16 (2*s*, 2 Me). ¹³C-NMR: 124.9 (*d*, C(2)); 126.0, 121.4 (2*s*, C(4), C(5)); 32.2 (*q*, MeN); 8.5, 7.2 (2*q*, 2 Me). CI-MS: 127 (89, $[M + 1]^+$), 126 (12, M^{++}), 111 (100), 97 (12). Anal. calc. for C₆H₁₀N₂O · 0.75 H₂O (139.61): C 51.63, H 8.32, N 20.06; found: C 51.38, H 9.00, N 19.88.

1-Ethyl-4,5-dimethylimidazole 3-Oxide (**1b**): 3 h; yield 377 mg (54%). Colorless crystals. M.p. $61-63^{\circ}$ (CH₂Cl₂/Et₂O). IR: 1660s, 1630s, 1470*m*, 1410s, 1395*s*, 1350s, 1160s. ¹H-NMR: 8.10 (*s*, H–C(2)); 3.94 (*q*, *J* = 7.2, MeCH₂); 2.19, 2.17 (2*s*, 2 Me); 1.39 (*t*, *J* = 7.2, MeCH₂). ¹³C-NMR: 126.1, 120.6 (2*s*, C(4), C(5)); 123.8 (*d*, C(2)); 40.6 (*t*, CH₂); 15.8, 8.5, 7.2 (3*q*, 3 Me). Anal. calc. for C₇H₁₂N₂O · 2 H₂O (176.22): C 47.71, H 9.15, N 15.90; found: C 47.53, H 9.03, N 15.76.

1-Benzyl-4,5-dimethylimidazole 3-Oxide (1c): yield 860 mg (85%). Colorless crystals. M.p. 197–199° ([11]: 199–201°).

1-Cyclohexyl-4,5-dimethylimidazole 3-Oxide (**1d**): 5 h; yield 2.63 g (90%). Colorless crystals. M.p. 198–200° (CH₂Cl₂/Et₂O). IR: 1620s, 1450s, 1410s, 1380s, 1360s, 1330vs, 1190s, 840s, 710s. ¹H-NMR: 7.84 (s, H–C(2)); 3.78 (m, CH); 2.18, 2.17 (2s, 2 Me); 2.05 – 1.2 (m, 10 H). ¹³C-NMR: 126.1, 120.2 (2s, C(4), C(5)); 121.8 (d, C(2)); 55.4 (d, CH); 33.8, 25.5, 24.9 (3t, 5 CH₂); 8.8, 7.2 (2q, 2 Me). CI-MS: 195 (6, $[M + 1]^+$), 180(11), 179(100), 117(6). Anal. calc. for C₁₁H₁₈N₂O · 0.5 H₂O (203.28): C 64.99, H 9.42, N 13.79; found: C 65.09, H 9.49, N 13.95.

1-Methyl-4,5-diphenylimidazole 3-Oxide (**1e**): 6 h; yield 763 mg (61%). Colorless crystals. M.p. $255-257^{\circ}$. IR: 1485*s*, 1440*s*, 1370*s*, 1345*s*, 1200*m*, 1055*s*, 870*m*, 825*s*, 770*vs*, 710*vs*, 670*s*. ¹H-NMR: 8.11 (*s*, H–C(2)); 7.55–7.25 (*m*, 10 arom. H); 3.55 (*s*, MeN). ¹³C-NMR: 130.6, 129.6, 129.5, 126.6 (4*s*, C(4), C(5), 2 arom. C); 129.1, 128.2, 128.1 (3*d*, 10 arom. CH, C(2)); 33.2 (*q*, MeN). CI-MS: 251 (12, $[M + 1]^+$), 236 (17), 235 (100). Anal. calc. for C₁₆H₁₄N₂O · 0.3 H₂O (255.70): C 75.16, H 5.76, N 10.95; found: C 75.34, H 5.58, N 10.94.

1-Ethyl-4,5-diphenylimidazole 3-Oxide (**1f**): 3 h; yield 990 mg (75%). Colorless crystals. M.p. 182–184° (CHCl₃/benzene). IR: 1600*m*, 1480*s*, 1445*s*, 1380*s*, 1345*vs*, 1250*s*, 1210*s*, 1080*s*, 1050*s*, 1030*s*, 850*s*, 760*vs*, 705*vs*, 675*s*. ¹H-NMR: 8.20 (*s*, H–C(2)); 7.55–7.25 (*m*, 10 arom. H); 3.87 (*q*, J = 7.2, MeCH₂); 1.31 (*t*, J = 7.2, MeCH₂): ¹³C-NMR: 130.6, 127.6, 127.0 (3*s*, C(4), C(5), 1 arom. C); 129.5, 129.1, 128.0, 125.5 (4*d*, C(2), 10 arom. CH); 41.3 (*t*, CH₂); 16.0 (*q*, Me). CI-MS: 265 (15, $[M + 1]^+$), 250 (18), 249 (100, $[M - 16]^+$), 173 (31). Anal. calc. for C₁₇H₁₆N₂O · H₂O (282.33): C 72.25, H 6.37, N 9.91; found: C 72.18, H 6.19, N 10.38.

1-Benzyl-4,5-diphenylimidazole 3-Oxide (**1g**): 2 h; yield 1.30 g (80%). Colorless crystals. M.p. $174-176^{\circ}$ (pentane/Et₂O) ([11]: $176-178^{\circ}$).

1-Cyclohexyl-4,5-diphenylimidazole 3-Oxide (**1h**): 6 h; yield 1.19 g (75%). Colorless crystals. M.p. 179–180° (CH₂Cl₂/Et₂O). IR: 2860s, 1640s, 1510s, 1480m, 1440s, 1360m, 1320s, 1300s, 1210s, 1040vs, 1020vs, 880vs, 770vs, 720vs, 700vs. ¹H-NMR: 8.18 (*s*, H–C(2)); 7.65–7.2 (*m*, 10 arom. H); 3.67 (*m*, CH); 1.85–1.05 (*m*, 10 H). ¹³C-NMR: 132.6, 129.1, 127.4, 124.8 (4*s*, C(4), C(5), 2 arom. C); 130.8, 130.7, 129.7, 129.6, 129.2, 128.1, 128.0, 127.9, 126.4 (9*d*, C(2), 10 arom. CH); 55.8 (*d*, CH); 34.0, 25.3, 24.5 (3*t*, 5 CH₂). CI-MS: 319 (5, $[M + 1]^+$), 303 (54), 302 (100).

4,5-Diphenyl-1-(2-phenylethyl)imidazole 3-Oxide (1i): 2 h; yield 1.26 g (74%). Colorless crystals. M.p. $185-187^{\circ}$ (benzene/petroleum ether; [11]: $188-190^{\circ}$).

1,5-Dimethyl-4-phenylimidazole 3-Oxide (1j): 3 h; yield 837 mg (89%). Colorless crystals. M.p. $201-202^{\circ}$ (CHCl₃/petroleum ether). IR: 3040s, 1605m, 1440s, 1380s, 1350s, 1250s, 1205m, 1030m, 770vs, 720s, 705s. ¹H-NMR: 7.96 (s, H–C(2)); 7.65–7.6 (m, 3 arom. H); 7.5–7.25 (m, 2 arom. H); 3.60, 2.28 (2s, 2 Me). ¹³C-NMR: 129.6, 128.4, 128.3 (3d, C(2), 5 arom. CH); 127.3, 125.5, 122.7 (3s, C(4), C(5), 1 arom. C); 32.4 (q, MeN); 9.4 (q, Me). CI-MS: 189 (14, $[M + 1]^+$), 188 (11, M^{++}), 174 (12), 173 (100), 159 (17). Anal. calc. for C₁₁H₁₂N₂O·H₂O (206.24): C 64.06, H 7.09, N 13.58; found: C 63.91, H 6.70, N 13.55.

1-Butyl-5-methyl-4-phenylimidazole 3-Oxide (1k): 1 h; yield 875 mg (76%). Colorless crystals. M.p. $155-157^{\circ}$ (benzene/petroleum ether; [11]: $157-158^{\circ}$).

3. Conversions of Imidazole 3-Oxides 1 to Imidazole-2(3H)-thiones 9. General Procedure. A cooled soln. $(H_2O/ice bath)$ of 5a (156 mg, 1 mmol)¹¹) in CHCl₃ (1 ml) was stirred magnetically, and a soln. of the corresponding N-oxide 1 (1 mmol) in CHCl₃ (1 ml) was added dropwise. Then, the cooling bath was removed and stirring continued for 1 h at r.t. The decolorized soln. with partially precipitated products were evaporated *in vacuo*, and solid residues were triturated with pentane (5 ml) to remove 2,2,4,4-tetramethylcyclobutane-1,3-dione (6a) formed as a by-product. The crude products were fairly pure and could be used for further reactions without purification. Anal. samples were prepared by subsequent recrystallization. Reported yields refer to imidazole-2(3H)-thione isolated after recrystallization.

1,4,5-Trimethylimidazole-2(3H)-thione (9a): 118 mg (85%). Colorless crystals. M.p. $212-214^{\circ}$ (EtOH). IR: 3020vs, 2960vs, 1660s, 1500s, 1440s, 1395s, 1260s, 1150m, 1110m, 795m. ¹H-NMR: 11.80 (br. s, NH); 3.50, 2.09, 2.06 (3s, 3 Me). ¹³C-NMR: 157.8 (s, C=S); 121.6, 119.9 (2s, C(4), C(5)); 31.1 (q, MeN); 9.0, 8.9 (2q, 2 Me). EI-MS: 143 (25, $[M + 1]^+$), 142 (100, M^{++}), 141 (65, $[M - 1]^+$), 127 (35, $[M - Me]^+$), 109 (44, $[M - SH]^+$), 100 (8), 82 (12), 71 (18), 68 (29). Anal. calc. for C₆H₁₀N₂S (142.22): C 50.67, H 7.09, N 19.70, S 19.88; found: C 50.46, H 7.38, N 19.46, S 19.70.

1-Ethyl-4,5-dimethylimidazole-2(3H)-thione (9b): 130 mg (83%). Colorless crystals. M.p. $183-184^{\circ}$ (CHCl₃). IR: 3000vs, 2880s, 2690m, 1660m, 1500s, 1470s, 1410s, 1390s, 1320s, 1255s, 1205m, 1140m, 1120m, 795s. ¹H-NMR: 10.5 (br. *s*, NH); 4.05 (*q*, *J* = 7.2, MeCH₂); 2.08 (*s*, 2 Me); 1.30 (*t*, *J* = 7.2, MeCH₂). ¹³C-NMR: 157.5 (*s*, C=S); 120.9, 119.9 (2*s*, C(4), C(5)); 39.4 (*t*, CH₂); 14.0, 9.0, 8.8 (3*q*, 3 Me). Anal. calc. for C₇H₁₂N₂S (156.25): C 53.81, H 7.74, N 17.93, S 20.52; found: C 53.86, H 8.07, N 17.81, S 20.86.

*1-Benzyl-4,5-dimethylimidazole-2(3*H)*-thione* (9c): 201 mg (92%). Colorless crystals. M.p. $227-228^{\circ}$ (CHCl₃). IR: 3020s, 1660s, 1500s, 1450s, 1405m, 1380m, 1370m, 1250m, 1240m, 1195m, 790m. ¹H-NMR: 10.75 (br. *s*, NH); 7.28 (br. *s*, 5 arom. H); 5.34 (*s*, CH₂); 2.11, 1.97 (2*s*, 2 Me). ¹³C-NMR: 160.1 (br. *s*, C=S); 135.8

¹¹) Identical reactions were observed using 154 mg (1 mmol) of adamantanethione (5c) or 86 mg (0.5 mmol) of 2,2,4,4-tetramethylcyclobutane-1,3-dithione (5b). Thiobenzophenone reacted significantly slower and decolorization of the soln. at r.t. was completed only after 30 h.

(*s*, 1 arom. C); 128.8, 127.7, 127.0 (3*d*, 5 arom. CH); 123.4, 109.5 (2*s*, C(4), C(5)); 48.1 (*t*, CH₂); 9.2, 9.1 (2*q*, 2 Me). EI-MS: 218 (100, M^{++}), 185 (43, $[M - SH]^+$), 127 (30, $[M - C_7H_7]^+$), 91 (79, $C_7H_7^+$). Anal. calc. for $C_{12}H_{14}N_2S$ (218.32): C 66.02, H 6.46, N 12.83, S 14.69; found: C 65.91, H 6.83, N 13.07, S 14.80.

*1-Cyclohexyl-4,5-dimethylimidazole-2(3*H)*-thione* (**9d**): 200 mg (95%). Colorless crystals. M.p. 221–223° (EtOH). IR: 3040vs, 2920vs, 2820vs, 2660s, 1660s, 1510s, 1455s, 1420s, 1400s, 1380s, 1280s, 1250s, 1120m, 1020m, 1000m, 800s. ¹H-NMR: 11.94 (br. *s*, NH); 4.86 (*m*, 1 H); 2.18, 2.06 (2*s*, 2 Me); 1.9–1.5 (br. *m*, 10 H). ¹³C-NMR: 157.2 (*s*, C=S); 121.1, 120.8 (2*s*, C(4), C(5)); 57.1 (*d*, CH); 30.6, 26.1, 25.4 (3*t*, 5 CH₂); 10.6, 8.9 (2*q*, 2 Me). EI-MS: 210 (54, M^{++}), 128 (100), 95 (7). Anal. calc. for C₁₁H₁₈N₂S (210.34): C 68.81, H 8.63, N 13.32, S 15.24; found: C 68.67, H 8.75, N 13.35, S 15.35.

*1-Methyl-4,5-diphenylimidazole-2(3*H)*-thione* (**9e**): 210 mg (79%). Colorless crystals. M.p. 279–281° (EtOH). IR: 2980*s*, 2880*s*, 1600*m*, 1495*s*, 1450*s*, 1430*s*, 1400*s*, 1385*s*, 1280*m*, 1145*m*, 800*s*. ¹H-NMR: 11.46 (br. *s*, NH); 7.5 – 7.25 (*m*, 10 arom. H); 3.49 (*s*, Me). ¹³C-NMR: 159.2 (*s*, C=S); 129.6, 128.5, 127.9 (3*s*, C(4), C(5), 2 arom. C); 130.7, 129.3, 128.8, 128.6, 126.6 (5*d*, 10 arom. CH); 32.6 (*q*, Me). EI-MS: 266 (100, M^{++}), 265 (100, $[M-1]^+$), 233 (8, $[M-SH]^+$), 232 (13), 207 (20), 206 (12), 193 (15), 165 (18), 133 (18), 118 (13), 104 (10), 77 (19). Anal. calc. for C₁₆H₁₄N₂S (266.36): C 72.16, H 5.30, N 10.53, S 12.02; found: C 72.19, H 5.42, N 10.54, S 11.93.

*1-Ethyl-4,5-diphenylimidazole-2(3*H)*-thione* (**9f**): 269 mg (96%). Colorless crystals. M.p. 292–294° (EtOH). IR: 3000*s*, 2880*s*, 1600*m*, 1510*s*, 1490*vs*, 1460*s*, 1405*s*, 1380*m*, 1260*s*, 1140*m*, 780*s*. ¹H-NMR: 11.05 (br. *s*, NH); 7.5–7.2 (*m*, 10 arom. H); 4.04 (*q*, MeCH₂); 1.21 (*t*, MeCH₂). ¹³C-NMR: 159.9 (*s*, C=S); 130.9, 128.0, 126.4 (3*s*, C(4), C(5), 1 arom. C); 129.7, 129.3, 128.8 (3*d*, 10 arom. CH); 40.3 (*t*, CH₂); 14.3 (*q*, Me). EI-MS: 280 (100, M^{++}), 279 (33, $[M-1]^+$), 252 (35), 240 (12), 193 (31), 165 (16), 104 (13), 103 (12), 77 (14). Anal. calc. for C₁₇H₁₆N₂S (280.39): C 72.82, H 5.75, N 9.99, S 11.43; found: C 72.54, H 6.05, N 10.05, S 11.28.

*1-Benzyl-4,5-diphenylimidazole-2(3*H)*-thione* (**9g**): 325 mg (95%). Colorless crystals. M.p. $268-270^{\circ}$ (CHCl₃). IR: 3020s, 2900s, 1600*m*, 1490s, 1480s, 1460s, 1405s, 1240s, 1205s, 1195s, 1090*m*, 790s, 780s. ¹H-NMR: 11.78 (br. *s*, NH); 7.45 – 7.0 (*m*, 15 arom. H); 5.26 (*s*, CH₂). ¹³C-NMR: 160.5 (br. *s*, C=S); 131.1, 128.5, 127.8 (3*s*, C(4), C(5), 3 arom. C); 129.5, 128.9, 128.7, 128.4, 128.0, 127.5, 127.4, 126.5 (8*d*, 15 arom. CH); 48.4 (*t*, CH₂). EI-MS: 343 (18, $[M + 1]^+$), 342 (75, M^+), 309 (24, $[M - SH]^+$), 193 (100), 178 (50), 165 (12), 91 (49), 77 (14). Anal. calc. for C₂₂H₁₈N₂S (342.46): C 77.16, H 5.30, N 8.18, S 9.36; found: C 77.00, H 4.99, N 8.16, S 9.16.

*1-Cyclohexyl-4,5-diphenylimidazole-2(3*H)*-thione* (**9**h): 318 mg (95%). Colorless crystals. M.p. $295-297^{\circ}$ (EtOH; [32]: $316-317^{\circ}$). ¹H-NMR: 10.36 (br. *s*, NH); 7.5–7.15 (*m*, 10 arom. H); 4.20 (*m*, 1 H); 1.8–1.2 (*m*, 10 H).

4,5-Diphenyl-1-(2-phenylethyl)imidazole-2(3H)-thione (9i): 314 mg (88%). Colorless crystals. M.p. 261–263° (acetone). IR: 3000vs, 2890s, 1600m, 1500vs, 1460s, 1410s, 1370s, 1270s, 1180s, 790s, 780s. ¹H-NMR: 10.10 (br. *s*, NH); 7.5–7.4, 7.25–7.15, 7.0–6.95 (3*m*, 15 arom. H); 4.16, 3.00 (2*t*, 2 CH₂). ¹³C-NMR: 154.0 (*s*, C=S); 131.0, 126.6, 126.3 (3*s*, C(4), C(5), 3 arom. C); 129.7, 129.2, 128.9, 128.8, 128.6, 128.1 (6*d*, 15 arom. CH); 46.6, 34.6 (2*t*, 2 CH₂). EI-MS: 356 (49, M^{++}), 252 (100, $[M - PhCH_2CH_2]^+$), 193(9), 165(9), 104 (12, PhCH₂CH₂⁺), 77(8). Anal. calc. for C₂₃H₂₀N₂S (356.49): C 77.49, H 5.65, N 7.86, S 8.99; found: C 77.77, H 5.95, N 7.86, S 9.00.

 $1,5-Dimethyl-4-phenylimidazole-2(3H)-thione (9j): 192 mg (94\%). Colorless crystals. M.p. 254-256^{\circ} (acetone; [33]: 247-249^{\circ}). 'H-NMR: 11.43 (br. s, NH); 7.45-7.25 (m, 5 arom. H); 3.60, 2.30 (2s, 2 Me).$

*1-Butyl-5-methyl-4-phenylimidazole-2(3*H)*-thione* (**9**k): 160 mg (65%). Colorless crystals. M.p. 285–287° (CHCl₃). IR: 3000vs, 2880vs, 1635m, 1600m, 1500vs, 1450s, 1410s, 1400s, 1370s, 1280s, 1250m, 1230m, 1190m, 1130s, 940m, 920m, 790s, 780s. ¹H-NMR: 11.53 (br. *s*, NH); 7.45–7.25 (*m*, 5 arom. H); 2.33 (*s*, Me); 4.07 (*t*, CH₂); 1.76, 1.44 (2m, 2 CH₂); 0.98 (*t*, *Me*CH₂). ¹³C-NMR ((D₆)DMSO): 159.7 (*s*, C=S); 138.6, 122.4, 121.2 (3*s*, C(4), C(5), 1 arom. C); 127.7, 125.8 (2*d*, 5 arom. CH); 42.4, 29.3, 18.5 (3*t*, 3 CH₂); 12.7, 8.8 (2*q*, 2 Me). EI-MS: 246 (99, *M*⁺⁺), 213 (100, [*M* – SH]⁺), 204 (32), 190 (66), 130 (14), 115 (10), 103 (13), 77 (9). Anal. calc. for C₁₄H₁₈N₂S (246.37): C 68.25, H 7.36, N 11.37, S 13.01; found: C 68.30, H 7.56, N 11.40, S 12.67.

Ethyl 4,5-*Dihydro-1-phenyl-5-thioxo-1,2,4-[1H]triazole-3-carboxylate* (11): Prepared according to the *General Procedure* described for imidazole 3-oxides 1 using triazole *N*-oxide 10 and 5a. Yield: 209 mg (84%). Colorless crystals. M.p. 196–198° (EtOH). IR: 2880s, 1740vs (C=O), 1600w, 1505m, 1470s, 1420m, 1390s, 1285s, 1240m, 1200s, 1105m, 1030m, 1020m, 805m, 790m, 700m. ¹H-NMR ((D₆)DMSO): 8.0–7.9, 7.55–7.4 (2m, 5 arom. H); 4.50 (q, MeCH₂); 1.44 (t, MeCH₂). ¹³C-NMR ((D₆)DMSO): 167.4 (s, C=S); 155.5, 137.3 (2s, C(3), 1 arom. C); 128.7, 128.4, 124.4 (3d, 5 arom. CH); 62.3 (t, CH₂); 13.8 (q, Me). EI-MS: 249 (100, M^{+*}), 220 (14, $[M - Et]^+$), 202 (20), 175 (34), 91 (42), 77 (23). Anal. calc. for C₁₁H₁₁N₃O₂S (249.29): C 53.00, H 4.45, N 16.86, S 12.86; found: C 52.91, H 4.56, N 16.85, S 12.71.

4. 'One-Pot' Procedure for the Synthesis of Imidazole-2(3H)-thione 9d. A soln. of 3d (220 mg, 0.65 mmol), 2a (200 mg, 2 mmol), and 5b (170 mg, 1 mmol) in abs. EtOH (5 ml) was heated under reflux. After 6 h, the

initially red mixture turned colorless, the solvent was evaporated, and the solid residue triturated with a small amount of Et₂O. After 1 h in the refrigerator, the crude product was filtered and recrystallized from CH_2Cl_2/Et_2O yielding 130 mg (61%) of **9d**. Colorless crystals. M.p. 220–222°.

5. Reactions of (tert-Butyl)(isopropyl)thioketene (12) with Heterocyclic N-Oxides. 5.1. Reaction with 1c. To a soln. of 1c (100 mg, 0.5 mmol) and 12 (78 mg, 0.5 mmol) in $CDCl_3$ (0.5 ml) in an NMR tube, 1,1,2,2-tetrachloroethane (136 mg, 0.81 mmol) was added as an internal standard. The tube was closed and stored at r.t. The initially red-blue soln. decolorized after 1 h. The ¹H-NMR spectrum showed well separated signals of *1*-benzyl-4,5-dimethylimidazole (14; s at 7.51 ppm, 1 H), 3-(tert-butyl)-3-isopropylthiiran-2-one 13 (s at 1.08 ppm, 9 H), and 9c (s at 5.28 ppm, 2 H), which allowed to establish the ratio of 14/13/9c/15 as 84:70:15:14.

5.2. *Reaction with Pyrimidine* N-*Oxide.* A soln. of pyrimidine *N*-oxide (96 mg, 1 mmol) and **12** (156 mg, 1 mmol) in CDCl₃ (1 ml) was placed in an NMR tube and stored at r.t. The initially red-violet color disappeared after 7 d. The ¹H-NMR spectrum of the crude mixture revealed the presence of **13** and pyrimidine in a ratio of 1:1. Chromatography on SiO₂-coated plates (hexane/CHCl₃ 6:4) yielded 140 mg (44%) of **13** as a colorless oil which showed identical IR absorptions as those described in [17]. ¹H-NMR: 2.66 (*sept.*, J = 6.0, Me_2CH); 1.08 (*s*, Me_3C); 1.08, 0.83 (2*d*, J = 6.0, Me_2CH). ¹³C-NMR: 190.1 (*s*, C=O); 59.2, 37.7 (2*s*, C(2), Me₃C); 28.4 (*d*, Me₂CH); 27.6 (*q*, Me_3C); 21.8, 19.9 (2*q*, Me_2CH). The polar fraction afforded 40 mg (50%) of pyrimidine.

6. Competitive Experiments of Imidazole 3-Oxides 1 and 5b. To a soln. of 1a (15.1 mg, 0.12 mmol), 1d (23.3 mg, 0.12 mmol), and 1,1,2,2-tetrachloroethane (26.2 mg, 0.16 mmol) in $CDCl_3$ (0.5 ml) in an NMR tube, a soln. of 5b (10.3 mg, 0.06 mmol) in $CDCl_3$ (0.3 ml) was added at r.t. by means of a syringe. The initially red mixture turned colorless after few s. After *ca*. 1 h, the mixture was analyzed by ¹H-NMR spectroscopy, and the yields of 9a and 9d were determined to 95 and 5%, respectively, in relation to CCl_4 as an internal standard.

In an analogous experiment with **1a**, **1c**, and **5b**, the yields of **9a** and **9c** were determined to 45 and 55%, respectively.

REFERENCES

- [1] L. Fišera, R. Huisgen, I. Kalwinsch, E. Langhals, X. Li, G. Mlostoń, K. Polborn, J. Rapp, W. Sicking, R. Sustmann, *Pure Appl. Chem.* **1996**, *68*, 789.
- [2] a) R. Huisgen, X. Li, Tetrahedron Lett. 1983, 24, 4185; b) R. Huisgen, E. Langhals, ibid. 1989, 30, 5369.
- [3] H. Giera, R. Huisgen, Liebigs Ann./Recl. 1997, 1685.
- [4] A. R. Katritzky, J. M. Lagowski, 'Chemistry of the Heterocyclic N-Oxides', Academic Press, London, 1971.
- [5] P. DeShong, S. W. Lander, Jr., J. M. Leginus, C. M. Dicken, in 'Advances in Cycloaddition', Ed. D. P. -Curre, JAI Press, London, 1988, Vol. 1, p. 87.
- [6] A. Padwa, A. M. Schoffstall, in 'Advances in Cycloaddition', Ed. D. P. Curren, JAI Press, London, 1990, Vol. 2, p. 1.
- [7] Y. Kurasawa, A. Takada, H. S. Kim, J. Heterocycl. Chem. 1995, 32, 1085.
- [8] A. W. Ryzhakov, L. L. Rodina, Khim. Geterotsikl. Soedin. 1992, 579.
- [9] H. Lettau, Z. Chem. 1970, 10, 211.
- [10] I. J. Ferguson, K. Schofield, J. Chem. Soc., Perkin Trans. 1 1975, 275.
- [11] R. Bartnik, W. Hahn, G. Mlostoń, Roczniki Chem. 1977, 51, 49 (CA: 1977, 87, 53155).
- [12] a) R. Bartnik, G. Mlostoń, *Roczniki Chem.* 1977, 51, 1747 (CA: 1978, 88, 62332); b) G. Mlostoń, unpublished results, USC Los Angeles, 1997.
- [13] S. Takahashi, H. Kano, Tetrahedron Lett. 1993, 1687; Chem. Pharm. Bull. 1964, 12, 1290.
- [14] M. Hamana, B. Umezawa, S. Nakashima, Chem. Pharm. Bull. 1962, 10, 969.
- [15] B. V. Trzhtsinskaya, N. D. Abramova, Sulfur Reports 1991, 10, 389.
- [16] N. V. Harris, C. Smith, M. J. Ashton, A. W. Bridge, R. C. Bush, E. C. J. Coffee, D. I. Dron, M. F. Harper, D. J. Lythgoe, C. G. Newton, D. Riddell, *J. Med. Chem.* **1992**, *35*, 4384.
- [17] E. Schaumann, U. Behrens, Angew. Chem. 1977, 89, 750.
- [18] D. St. C. Black, K. G. Watson, Aust. J. Chem. 1973, 26, 2491.
- [19] J. Elguero, C. Marzin, A. R. Katritzky, P. Linda, 'The Tautomerism of Heterocycles', Academic Press, New York, 1976, p. 396ff.
- [20] G. Mlostoń, A. Linden, H. Heimgartner, Helv. Chim. Acta 1991, 74, 1386.
- [21] L. Kahovec, Z. Phys. Chem., B 1939, 43, 364.
- [22] J. Graymore, J. Chem. Soc. 1932, 1353.
- [23] J. Graymore, J. Chem. Soc. 1935, 865.

Helvetica Chimica Acta - Vol. 81 (1998)

- [24] L. Stefaniak, T. Urbanski, M. Witanowski, H. Januszewski, *Roczniki Chem.* **1969**, *59*, 1687 (*CA*: **1970**, *72*, 210726).
- [25] W. L. Semon, V. R. Damerell, Org. Synth. 1943, 2, 205.
- [26] T. Watson, J. Taylor, M. S. Marks, J. Chem. Soc. 1930, 2302.
- [27] W. F. Beech, J. Chem. Soc. 1955, 3095.
- [28] E. V. Elam, H. W. Davis, J. Org. Chem. 1967, 32, 1562.
- [29] J. W. Greidanus, Can. J. Chem. 1970, 48, 3530.
- [30] H. Bredereck, R. Gompper, H. Herlinger, Chem. Ber. 1958, 91, 2832.
- [31] R. Huisgen, R. Grashey, E. Aufderhaar, R. Kuntz, Chem. Ber. 1965, 98, 642.
- [32] V. B. Kaltscheva, L. J. Tsvetanska, Khim. Geterotsikl. Soedin. 1981, 1028.
- [33] T. Kobayashi, H. Fujieda, Y. Murakami, T. Nakamura, K. Ono, S. Yamamoto, H. Kato, Bull. Chem. Soc. Jpn. 1994, 67, 3082.

Received June 15, 1998